2021
DOI: 10.1016/j.ijrobp.2021.03.003
|View full text |Cite
|
Sign up to set email alerts
|

The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
29
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(31 citation statements)
references
References 41 publications
1
29
1
Order By: Relevance
“…Recently, increasing evidences show that TIME is closely related to the development of cervical carcinoma and has an important value in OS or the prognosis of cervical carcinoma [5,7]. Emerging evidence has elucidated that tumors can act as distinct immunological organs with complex TIME, and the immune cells recruited and activated in TIME are linked to the malignant phenotypes of tumors [13,19].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, increasing evidences show that TIME is closely related to the development of cervical carcinoma and has an important value in OS or the prognosis of cervical carcinoma [5,7]. Emerging evidence has elucidated that tumors can act as distinct immunological organs with complex TIME, and the immune cells recruited and activated in TIME are linked to the malignant phenotypes of tumors [13,19].…”
Section: Discussionmentioning
confidence: 99%
“…Recently reports showed that the metastasis and invasion of cervical carcinoma are closely related to the tumor immune microenvironment (TIME), and targeted therapy for its TIME has been more and more developed and applied [5][6][7][8]. The cervical carcinoma progresses in TIME mainly composed of infiltrating immune and stromal cells.…”
Section: Introductionmentioning
confidence: 99%
“…In our study, the high expression of LAG3 and PDCD1 was associated with poor prognosis in cervical cancer patients. Rui Li [40] et al conducted a prospective clinical trial to assess the tumor immune microenvironment during CCRT of patients with LACC, and they suggested that immune checkpoint inhibitors were administered before CCRT maybe more effective.…”
Section: Discussionmentioning
confidence: 99%
“…Previous studies have advanced the understanding of how CCRT regulates the activation of systemic immune by analyzing the immune checkpoints of tumor biopsy and T lymphocyte populations in peripheral blood mononuclear cells (PBMCs). CCRT can modify the tumor immune microenvironment by reducing the PD-1/PD-L1 expression and upregulating the CD28 costimulation signal [ 7 , 8 ]. Besides, Li et al found the increasing number of CD4 + and CD8 + T cells and the decreasing number of inhibitory regulatory T cells in PBMCs after CCRT [ 8 ].…”
Section: Introductionmentioning
confidence: 99%